|
1
|
Lynch HT, Snyder C and Casey MJ:
Hereditary ovarian and breast cancer: What have we learned? Ann
Oncol. 24 Suppl 8:viii83–viii95. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kucukmetin A, Naik R, Galaal K, Bryant A
and Dickinson HO: Palliative surgery versus medical management for
bowel obstruction in ovarian cancer. Cochrane Database Syst Rev.
7:CD0077922010.
|
|
3
|
Keen A, Fitzgerald D, Bryant A and
Dickinson HO: Management of drainage for malignant ascites in
gynaecological cancer. Cochrane Database Syst Rev.
1:CD0077942010.
|
|
4
|
Khosravi-Shahi P and Cabezon-Gutierrez L:
Antiangiogenic drugs in the treatment of advanced epithelial
ovarian cancer. Anticancer Agents Med Chem. 12:982–987. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhatt P, Vhora I, Patil S, Amrutiya J,
Bhattacharya C, Misra A and Mashru R: Role of antibodies in
diagnosis and treatment of ovarian cancer: Basic approach and
clinical status. J Control Release. 226:148–167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen DF, Liu X, Yang XF, Fang L, Gao Y,
Zhao S, Wu JC, Shi S, Li JJ, Zhao XX, et al: The roles of
parafibromin expression in ovarian epithelial carcinomas: A marker
for differentiation and prognosis and a target for gene therapy.
Tumour Biol. 37:2909–2924. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li W, Zhou Y, Su Y, Ouyang Y, Xie X, Wu Y,
Mao C and Chen D: IL-23 promotes invasion of esophageal squamous
cell carcinoma cells by activating DLL4/Notch1 signaling pathway.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 31:812–815, 820. 2015.(In
Chinese). PubMed/NCBI
|
|
8
|
Stuckey A, Fischer A, Miller DH,
Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L and
Brodsky AS: Integrated genomics of ovarian xenograft tumor
progression and chemotherapy response. BMC Cancer. 11:3082011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sabe H, Hashimoto S, Morishige M, Ogawa E,
Hashimoto A, Nam JM, Miura K, Yano H and Onodera Y: The
EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer
invasion and metastasis. Traffic. 10:982–993. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Caviston JP, Cohen LA and Donaldson JG:
Arf1 and Arf6 promote ventral actin structures formed by acute
activation of protein kinase C and Src. Cytoskeleton. 71:380–394.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stearns T, Willingham MC, Botstein D and
Kahn RA: ADP-ribosylation factor is functionally and physically
associated with the Golgi complex. Proc Natl Acad Sci USA.
87:1238–1242. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robertson DN, Johnson MS, Moggach LO,
Holland PJ, Lutz EM and Mitchell R: Selective interaction of ARF1
with the carboxy-terminal tail domain of the 5-HT2A receptor. Mol
Pharmacol. 64:1239–1250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cohen LA, Honda A, Varnai P, Brown FD,
Balla T and Donaldson JG: Active Arf6 recruits ARNO/cytohesin GEFs
to the PM by binding their PH domains. Mol Biol Cell. 18:2244–2253.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hassa PO, Haenni SS, Elser M and Hottiger
MO: Nuclear ADP-ribosylation reactions in mammalian cells: Where
are we today and where are we going? Microbiol Mol Biol Rev.
70:789–829. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Norman JC, Jones D, Barry ST, Holt MR,
Cockcroft S and Critchley DR: ARF1 mediates paxillin recruitment to
focal adhesions and potentiates Rho-stimulated stress fiber
formation in intact and permeabilized Swiss 3T3 fibroblasts. J Cell
Biol. 143:1981–1995. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Viaud J, Zeghouf M, Barelli H, Zeeh JC,
Padilla A, Guibert B, Chardin P, Royer CA, Cherfils J and Chavanieu
A: Structure-based discovery of an inhibitor of Arf activation by
Sec7 domains through targeting of protein-protein complexes. Proc
Natl Acad Sci USA. 104:10370–10375. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boulay PL, Cotton M, Melançon P and Claing
A: ADP-ribosylation factor 1 controls the activation of the
phosphatidylinositol 3-kinase pathway to regulate epidermal growth
factor-dependent growth and migration of breast cancer cells. J
Biol Chem. 283:36425–36434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schlienger S, Ramirez RA and Claing A:
ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells
through formation of focal adhesions. Cell Signal. 27:403–415.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Frame MC: Src in cancer: Deregulation and
consequences for cell behaviour. Biochim Biophys Acta.
1602:114–130. 2002.PubMed/NCBI
|
|
20
|
Wheeler DL, Iida M and Dunn EF: The role
of Src in solid tumors. Oncologist. 14:667–678. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji L, Li H, Gao P, Shang G, Zhang DD,
Zhang N and Jiang T: Nrf2 pathway regulates
multidrug-resistance-associated protein 1 in small cell lung
cancer. PLoS One. 8:e634042013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Liu F, Mao F, Hang Q, Huang X, He
S, Wang Y, Cheng C, Wang H, Xu G, et al: Interaction with cyclin
H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal
binding protein 2 (CtBP2) and promotes cancer cell migration. J
Biol Chem. 288:9028–9034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Yang S, Ni Q, He S, Zhao Y, Yuan
Q, Li C, Chen H, Zhang L, Zou L, et al: Overexpression of forkhead
box J2 can decrease the migration of breast cancer cells. J Cell
Biochem. 113:2729–2737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kyriakidis I and Papaioannidou P: Estrogen
receptor beta and ovarian cancer: A key to pathogenesis and
response to therapy. Arch Gynecol Obstet. 293:1161–1168. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ara I, Bakir MA and Kudo T: Transfer of
Catellatospora koreensis Lee et al. 2000 as Catelliglobosispora
koreensis gen. nov., comb. nov. and Catellatospora tsunoense Asano
et al. 1989 as Hamadaea tsunoensis gen. nov., comb. nov., and
emended description of the genus Catellatospora Asano and Kawamoto
1986 emend. Lee and Hah 2002. Int J Syst Evol Microbiol.
58:1950–1960. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chun J, Shapovalova Z, Dejgaard SY,
Presley JF and Melançon P: Characterization of class I and II
ADP-ribosylation factors (Arfs) in live cells: GDP-bound class II
Arfs associate with the ER-Golgi intermediate compartment
independently of GBF1. Mol Biol Cell. 19:3488–3500. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ben-Tekaya H, Kahn RA and Hauri HP: ADP
ribosylation factors 1 and 4 and group VIA phospholipase A(2)
regulate morphology and intraorganellar traffic in the endoplasmic
reticulum-Golgi intermediate compartment. Mol Biol Cell.
21:4130–4140. 2010.doi: 10.1091/mbc.E10-01–0022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Burke JE and Williams RL: Dynamic steps in
receptor tyrosine kinase mediated activation of class IA
phosphoinositide 3-kinases (PI3K) captured by H/D exchange
(HDX-MS). Adv Biol Regul. 53:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishida K, Yamasaki S, Hasegawa A,
Iwamatsu A, Koseki H and Hirano T: Gab2, via PI-3K, regulates ARF1
in FcεRI-mediated granule translocation and mast cell
degranulation. J Immunol. 187:932–941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Orlichenko L, Stolz DB, Noel P, Behari J,
Liu S and Singh VP: ADP-ribosylation factor 1 protein regulates
trypsinogen activation via organellar trafficking of procathepsin B
protein and autophagic maturation in acute pancreatitis. J Biol
Chem. 287:24284–24293. 2012. View Article : Google Scholar : PubMed/NCBI
|
